ACADIA Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 5, 2016
May 02 2016 - 4:01PM
Business Wire
ACADIA to Host Conference Call and Webcast on
Thursday, May 5, 2016, at 5:00 p.m. Eastern Time
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical
company focused on the development and commercialization of
innovative medicines that address unmet medical needs in central
nervous system disorders, today announced that it will report its
unaudited financial results for the first quarter ended March 31,
2016 on Thursday, May 5, 2016, after the U.S. financial markets
close. ACADIA's management will host a conference call and webcast
on Thursday, May 5, 2016, at 5:00 p.m. Eastern Time to discuss
ACADIA’s financial results and operations.
The conference call may be accessed by dialing 844-821-1109 for
participants in the United States or Canada and 830-865-2550 for
international callers (reference passcode 5151879). A telephone
replay of the conference call may be accessed through May 19, 2016
by dialing 855-859-2056 for callers in the United States or Canada
and 404-537-3406 for international callers (reference passcode
5151879). The conference call also will be webcast live on ACADIA’s
website, www.acadia-pharm.com under the investors section and will
be archived there until May 19, 2016.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development
and commercialization of innovative medicines to address unmet
medical needs in central nervous system disorders. ACADIA maintains
a website at www.acadia-pharm.com to which we regularly post copies
of our press releases as well as additional information and through
which interested parties can subscribe to receive e-mail
alerts.
Forward-Looking Statements
Statements in this press release that are not strictly
historical in nature are forward-looking statements. These
statements include but are not limited to statements related to the
progress and timing of ACADIA’s drug discovery and development
programs, and the benefits to be derived from ACADIA’s product
candidates, in each case including NUPLAZID (pimavanserin). These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks and uncertainties inherent in drug discovery, development,
approval and commercialization, and in collaborations with others,
and the fact that past results of clinical trials may not be
indicative of future trial results. For a discussion of these and
other factors, please refer to ACADIA’s annual report on Form 10-K
for the year ended December 31, 2015 as well as ACADIA’s subsequent
filings with the Securities and Exchange Commission. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. This caution is
made under the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. All forward-looking statements are
qualified in their entirety by this cautionary statement and ACADIA
undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof, except as
required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160502005962/en/
ACADIA Pharmaceuticals Inc.Lisa Barthelemy, Investor
Relations(858) 558-2871
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2023 to Apr 2024